Companies › Verastem
3 active drug programs in 42 registered trials: 25 Phase 2, 15 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| avutometinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation … | Dec 2026 |
| defactinib Focal adhesion kinase 1 inhibitor; Protein tyrosine kinase 2 beta inhibitor | PTK2, PTK2B | Phase 3 | Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation … | Dec 2026 |
| VS-7375 KRAS G12D inhibitor | KRAS | Phase 2 | Colorectal Cancer; Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Ductal Adenocarcinoma | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03875820 | avutometinib | Phase 1 | NSCLC | Oncology | Apr 2023 |
| NCT03875820 | defactinib | Phase 1 | NSCLC | Oncology | Apr 2023 |
| NCT04625270 | avutometinib | Phase 2 | Low Grade Ovarian Serous Adenocarcinoma | Oncology | Dec 2026 |
| NCT04625270 | defactinib | Phase 2 | Low Grade Ovarian Serous Adenocarcinoma | Oncology | Dec 2026 |
| NCT04439331 | defactinib | Phase 2 | Advanced Lymphoma | Oncology | Jan 2027 |
| NCT05787561 | avutometinib | Phase 2 | Mesonephric Gynecologic Cancer | Oncology | Mar 2027 |
| NCT05787561 | defactinib | Phase 2 | Mesonephric Gynecologic Cancer | Oncology | Mar 2027 |
| NCT05074810 | avutometinib | Phase 1 | Non Small Cell Lung Cancer | Oncology | Apr 2027 |
| NCT06394804 | avutometinib | Phase 2 | Low-Grade Serous Ovarian Cancer | Oncology | Apr 2027 |
| NCT05074810 | defactinib | Phase 1 | Non Small Cell Lung Cancer | Oncology | Apr 2027 |
| NCT06394804 | defactinib | Phase 2 | Low-Grade Serous Ovarian Cancer | Oncology | Apr 2027 |
| NCT04331041 | defactinib | Phase 2 | Pancreas Cancer | Oncology | Apr 2027 |
| NCT07659795 | VS-7375 | Phase 2 | Colorectal Cancer | Oncology | Jun 2027 |
| NCT07659782 | VS-7375 | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT07644559 | VS-7375 | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | Oncology | Jun 2027 |
| NCT06007924 | avutometinib | Phase 2 | Thyroid Cancer | Oncology | Aug 2027 |
| NCT06007924 | defactinib | Phase 2 | Thyroid Cancer | Oncology | Aug 2027 |
| NCT05669482 | avutometinib | Phase 1 | KRAS Activating Mutation | Oncology | Aug 2027 |
| NCT05669482 | defactinib | Phase 1 | KRAS Activating Mutation | Oncology | Aug 2027 |
| NCT06682572 | avutometinib | Phase 2 | Low Grade Serous Ovarian Cancer | Oncology | Oct 2027 |
| NCT06682572 | defactinib | Phase 2 | Low Grade Serous Ovarian Cancer | Oncology | Oct 2027 |
| NCT05512208 | avutometinib | Phase 2 | Endometrioid Cancer | Oncology | Dec 2027 |
| NCT05512208 | defactinib | Phase 2 | Endometrioid Cancer | Oncology | Dec 2027 |
| NCT05636514 | defactinib | Phase 1 | Myelodysplastic Syndromes | Oncology | Dec 2027 |
| NCT05608252 | avutometinib | Phase 1 | Breast Cancer | Oncology | Dec 2027 |
| NCT06194929 | avutometinib | Phase 1 | Cutaneous Melanoma | Oncology | Jan 2028 |
| NCT06194929 | defactinib | Phase 1 | Cutaneous Melanoma | Oncology | Jan 2028 |
| NCT07318324 | avutometinib | Phase 1 | Phase IB | Oncology | Aug 2028 |
| NCT07318324 | defactinib | Phase 1 | Phase IB | Oncology | Aug 2028 |
| NCT06072781 | avutometinib | Phase 3 | Low Grade Serous Ovarian Cancer | Oncology | Oct 2028 |
| NCT06072781 | defactinib | Phase 3 | Low Grade Serous Ovarian Cancer | Oncology | Oct 2028 |
| NCT06487221 | avutometinib | Phase 2 | Gastric Cancer | Oncology | Nov 2028 |
| NCT06487221 | defactinib | Phase 2 | Gastric Cancer | Oncology | Nov 2028 |
| NCT07020221 | VS-7375 | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Dec 2028 |
| NCT06369259 | avutometinib | Phase 2 | Advanced Colorectal Cancer | Oncology | Feb 2029 |
| NCT06369259 | defactinib | Phase 2 | Advanced Colorectal Cancer | Oncology | Feb 2029 |
| NCT06495125 | avutometinib | Phase 2 | Advanced Lung Adenocarcinoma | Oncology | Mar 2029 |
| NCT06495125 | defactinib | Phase 2 | Advanced Lung Adenocarcinoma | Oncology | Mar 2029 |
| NCT06630260 | avutometinib | Phase 1 | Glioblastoma Multiforme (GBM) | Oncology | Sep 2029 |
| NCT06630260 | defactinib | Phase 1 | Glioblastoma Multiforme (GBM) | Oncology | Sep 2029 |
| NCT07126158 | avutometinib | Phase 2 | Pancreatic Adenocarcinoma | Oncology | Apr 2030 |
| NCT07126158 | defactinib | Phase 2 | Pancreatic Adenocarcinoma | Oncology | Apr 2030 |
Cash and short-term investments of $173m on 2026-09-30; operating cash outflow about $174m a year; runway about 12 months at that burn, to Sep 2027; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Immuneering Aura Biosciences InxMed (Shanghai) UroGen Pharma Can-Fite BioPharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.